Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

NCT03639246 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: AVB-S6-500
DRUG: Paclitaxel (Pac)
DRUG: Pegylated liposomal doxorubicin (PLD)
OTHER: Placebo

Sponsor

Aravive, Inc.